Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nogapendekin alfa inbakicept + tislelizumab
- Development stage
- Unknown
- Lead developer
- ImmunityBio
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
A combination therapy consisting of nogapendekin alfa inbakicept (an IL-15 superagonist) and tislelizumab (an anti-PD-1 monoclonal antibody). Nogapendekin alfa inbakicept (N-803) is a recombinant human IL-15 mutant (N72D) protein complexed with a soluble IL-15 receptor alpha (IL-15Rα) Fc fusion protein, designed to stimulate NK cells and CD8+ T cells. Tislelizumab is a humanized IgG4 monoclonal antibody that binds to PD-1, preventing it from interacting with PD-L1 and PD-L2. The combination aims to enhance antitumor immunity by simultaneously blocking the PD-1 checkpoint and providing IL-15-mediated immune stimulation. It is currently in Phase 3 development for non-small cell lung cancer (NSCLC).
- Other names
- N-803 + tislelizumabNAI + tislelizumab
02
Targets
FCGR1A (High affinity immunoglobulin gamma fc receptor I)IL15RA (Interleukin-15 receptor subunit alpha)IL2RB (IL-2 receptor beta chain)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on nogapendekin alfa inbakicept + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nogapendekin alfa inbakicept + tislelizumab.